Duration Associated with Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib
the Cancer Therapy Advisor take:
According to a new study published in the journal Digestive Diseases, researchers have found that the duration of stability is linked with overall survival in patients with advanced hepatocellular carcinoma treated with the tyrosine kinase inhibitor sorafenib.
For the study, researchers identified 269 patients with advanced hepatocellular carcinoma who were treated with sorafenib at the Kinki University Hospital in Japan between May 2009 and January 2013.
Of those 269, 158 patients' antitumor response of sorafenib were analyzed and patients were either classified as having a short period of stable disease (<3 months) or a long period of stable disease (≥3 months).
Results showed patients classified as having short stable disease had a median overall survival of 5.7 months and patients in the long stable disease had a median overall survival of 20.8 months. Patients with a complete response or a partial response had a median overall survival of 17.9 months.
The results suggest an association between patients who have a long duration of stable disease and overall survival.
Duration of stability linked with overall survival when treated with the tyrosine kinase inhibitor sorafenib.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer